https://kyleserikawa.com/2017/11/27/sequencing-in-polio-baseball-pitching-and-cancer-sometimes-the-order-of-events-matters/https://kyleserikawa.com/wp-content/uploads/2017/11/fig-2-5.pngfig 2.5https://kyleserikawa.com/wp-content/uploads/2017/11/fig-1.pngfig 1https://kyleserikawa.com/wp-content/uploads/2017/11/fig-2.pngfig 2https://kyleserikawa.com/wp-content/uploads/2017/11/fig-3.pngfig 3https://kyleserikawa.com/wp-content/uploads/2017/11/fig-4.pngfig 42017-11-27T18:54:45+00:00monthlyhttps://kyleserikawa.com/2017/10/31/whats-the-role-of-experts-a-review-of-the-death-of-expertise-and-some-thoughts-for-biopharma/https://kyleserikawa.com/wp-content/uploads/2017/10/macarthur-tweet.pngmacarthur tweet2017-10-31T15:12:06+00:00monthlyhttps://kyleserikawa.com/2017/08/01/how-plants-in-space-might-be-a-cautionary-tale-for-precision-medicine/2017-08-01T16:40:31+00:00monthlyhttps://kyleserikawa.com/2017/05/22/lessons-from-pcsk9-and-how-we-know-where-to-go-in-drug-discovery/https://kyleserikawa.com/wp-content/uploads/2017/05/pdl1.pngPDl12017-05-22T15:23:07+00:00monthlyhttps://kyleserikawa.com/2017/04/24/why-every-biopharma-lab-should-have-a-3d-printer-and-a-laser-cutter-too/2017-04-24T15:36:27+00:00monthlyhttps://kyleserikawa.com/2017/02/22/changing-small-molecule-exclusivity-rules-as-a-long-term-drug-price-policy-play/2017-02-22T15:07:29+00:00monthlyhttps://kyleserikawa.com/2017/01/31/its-time-for-biopharma-to-embrace-public-health/2017-01-31T18:25:37+00:00monthlyhttps://kyleserikawa.com/2016/11/15/how-valeant-anthem-and-chirping-crickets-suggest-saunders-social-contract-is-doomed/2023-05-15T14:03:20+00:00monthlyhttps://kyleserikawa.com/2016/09/20/want-to-help-biopharmas-reputation-problem-tackle-poverty/2016-09-20T20:34:24+00:00monthlyhttps://kyleserikawa.com/2016/08/04/plan-b/2016-08-04T17:10:01+00:00monthlyhttps://kyleserikawa.com/bc-bike-trip-2013/https://kyleserikawa.com/wp-content/uploads/2013/12/hummingbird-bus1.jpghummingbird bushttps://kyleserikawa.com/wp-content/uploads/2013/12/montague-bay.jpgMontague Bayhttps://kyleserikawa.com/wp-content/uploads/2013/12/bike-trip-table.jpgBike Trip Tablehttps://kyleserikawa.com/wp-content/uploads/2013/12/trail-view-galiano-21.jpgTrail view Galiano 2https://kyleserikawa.com/wp-content/uploads/2013/12/trail-view-galiano-11.jpgTrail view Galiano 1https://kyleserikawa.com/wp-content/uploads/2013/12/sandstone-2.jpgSandstone 2https://kyleserikawa.com/wp-content/uploads/2013/12/sandstone-1.jpgSandstone 1https://kyleserikawa.com/wp-content/uploads/2013/12/tent-site.jpgTent sitehttps://kyleserikawa.com/wp-content/uploads/2013/12/manzanita.jpgManzanitahttps://kyleserikawa.com/wp-content/uploads/2013/12/hummingbird-bus.jpghummingbird bus2016-07-24T03:04:21+00:00weekly0.6https://kyleserikawa.com/2016/07/18/how-brexit-changed-the-way-i-look-at-biopharmas-reputation-problem/2020-07-12T08:28:54+00:00monthlyhttps://kyleserikawa.com/2016/06/02/how-distributed-rd-could-spark-entrepreneurship-in-biopharma/2016-06-08T15:37:57+00:00monthlyhttps://kyleserikawa.com/2016/03/28/one-way-to-improve-clinical-trial-reporting-a-yelp-style-rating-system/2016-03-28T15:39:14+00:00monthlyhttps://kyleserikawa.com/2016/03/10/no-crispr-cas-wont-save-the-day-for-ag-biotech/2016-03-11T17:33:16+00:00monthlyhttps://kyleserikawa.com/2016/02/22/should-basic-lab-experiments-be-blinded-to-chip-away-at-the-reproducibility-problem/2016-02-24T19:06:24+00:00monthlyhttps://kyleserikawa.com/2015/12/19/google-knows-whats-in-your-inbox-but-it-shouldnt-get-your-genome-without-consent/2015-12-19T23:30:14+00:00monthlyhttps://kyleserikawa.com/2015/10/05/the-immune-system-as-a-metaphor-for-the-turing-pharma-mess/2015-10-06T04:45:46+00:00monthlyhttps://kyleserikawa.com/2015/05/18/baseball-regression-to-the-mean-and-avoiding-potential-clinical-trial-biases/https://kyleserikawa.com/wp-content/uploads/2015/05/test2.pngtest2https://kyleserikawa.com/wp-content/uploads/2015/05/averages-table.pngaverages table2015-05-18T15:42:39+00:00monthlyhttps://kyleserikawa.com/2015/05/14/an-open-standard-for-apis-could-lead-us-to-better-health/2015-05-14T15:18:46+00:00monthlyhttps://kyleserikawa.com/2014/11/11/is-opower-the-model-for-getting-us-to-wellness-and-health/https://kyleserikawa.com/wp-content/uploads/2014/11/2013-state-obesity-prevalence-map-labels.png2013-state-obesity-prevalence-map-labels2015-05-05T04:32:02+00:00monthlyhttps://kyleserikawa.com/2015/03/30/making-change/2015-03-30T16:34:38+00:00monthlyhttps://kyleserikawa.com/2015/01/27/baseball-bayes-fisher-and-the-problem-of-the-well-trained-mind/https://kyleserikawa.com/wp-content/uploads/2015/01/standard-of-care.pngStandard of Carehttps://kyleserikawa.com/wp-content/uploads/2015/01/precision-medicine.pngPrecision medicine2015-01-27T18:04:01+00:00monthlyhttps://kyleserikawa.com/2015/01/19/some-mlk-day-thoughts-about-evolution-teachable-moments-and-being-human/2015-01-27T17:45:32+00:00monthlyhttps://kyleserikawa.com/2014/12/01/could-pro-sports-lead-us-to-wellness/https://kyleserikawa.com/wp-content/uploads/2014/11/coaching_trees-wikipedia.gifCoaching_Trees wikipediahttps://kyleserikawa.com/wp-content/uploads/2014/11/coaching-table.pngCoaching table2014-12-03T01:08:12+00:00monthlyhttps://kyleserikawa.com/2014/11/04/trying-to-figure-the-way-through-a-401k-life/2014-11-08T05:27:15+00:00monthlyhttps://kyleserikawa.com/2014/10/13/the-potential-for-found-research-in-fecal-transplant-treatments/2022-12-03T09:59:13+00:00monthlyhttps://kyleserikawa.com/2014/07/07/baseball-analytics-arthritis-and-the-search-for-better-health-forecasts/https://kyleserikawa.com/wp-content/uploads/2014/07/subchallenge-1-graph.pngSubchallenge 1 graphhttps://kyleserikawa.com/wp-content/uploads/2014/07/gpr-model.jpgGPR Model2014-07-07T22:21:20+00:00monthlyhttps://kyleserikawa.com/2014/06/26/add-big-data-to-the-things-the-supreme-court-justices-know-when-they-see-them/2014-06-26T16:11:12+00:00monthlyhttps://kyleserikawa.com/2014/06/05/big-data-and-baseball-efficiency-the-traveling-salesman-had-nothing-on-a-baseball-scout/2014-06-05T20:21:07+00:00monthlyhttps://kyleserikawa.com/2014/05/28/the-power-law-relationship-in-drug-development/https://kyleserikawa.com/wp-content/uploads/2014/05/nate-silver-graph-small.jpgNate Silver graph small2014-05-28T19:57:24+00:00monthlyhttps://kyleserikawa.com/2014/05/09/drug-development-and-the-nfl-draft/https://kyleserikawa.com/wp-content/uploads/2014/05/paine-nfldraftefficientmarket-1.pngpaine-nfldraftefficientmarket-12014-05-09T19:53:54+00:00monthlyhttps://kyleserikawa.com/2014/05/05/the-fall-and-rise-of-the-lego-kingdom-a-review-of-brick-by-brick/https://kyleserikawa.com/wp-content/uploads/2014/04/brick-by-brick-small.jpgBrick By Brick small2014-05-05T16:37:10+00:00monthlyhttps://kyleserikawa.com/2013/12/03/the-innovators-dilemma-in-biopharma-part-2-where-are-the-markets-for-disruptive-tech/https://kyleserikawa.com/wp-content/uploads/2013/11/table-11.pngtable 1https://kyleserikawa.com/wp-content/uploads/2013/11/table-1.pngtable 1https://kyleserikawa.com/wp-content/uploads/2013/11/figure-2.jpgFigure 22014-04-16T17:52:55+00:00monthlyhttps://kyleserikawa.com/2014/04/16/the-innovators-dilemma-in-biopharma-part-3-what-would-disruption-look-like/https://kyleserikawa.com/wp-content/uploads/2014/04/adaptive-landscape-2.jpgadaptive landscape 22014-04-16T15:16:11+00:00monthlyhttps://kyleserikawa.com/2014/01/27/big-data-and-public-health-an-interview-with-dr-willem-van-panhuis-about-project-tycho-digitizing-disease-records-and-new-ways-of-doing-research-in-public-health/https://kyleserikawa.com/wp-content/uploads/2014/01/projecttycho_visuals_slide1.jpgProjectTycho_visuals_slide1https://kyleserikawa.com/wp-content/uploads/2014/01/vanpanhuiswilbertbriancohen20131113-12_resized.jpgvanPanhuis,Wilbert[brianCohen20131113] (12)_resized2014-01-27T18:07:06+00:00monthlyhttps://kyleserikawa.com/2014/01/15/how-good-are-sports-managers-suggestions-from-studies-of-bosses/https://kyleserikawa.com/wp-content/uploads/2014/01/equation-for-effort.pngEquation for effort2014-01-16T05:49:39+00:00monthlyhttps://kyleserikawa.com/2014/01/08/the-aussie-pipeline-to-the-slopes-of-british-columbia/2014-01-08T18:34:42+00:00monthlyhttps://kyleserikawa.com/2013/11/20/the-innovators-dilemma-in-biopharma-part-1-framing-the-industrys-position/https://kyleserikawa.com/wp-content/uploads/2013/11/figure-1.pngFigure 12013-12-22T04:14:12+00:00monthlyhttps://kyleserikawa.com/2013/12/19/big-data-provide-yet-more-big-proof-of-the-power-of-vaccines/https://kyleserikawa.com/wp-content/uploads/2013/12/vaccine-paper-figure-2b1.jpgvaccine paper Figure 2Bhttps://kyleserikawa.com/wp-content/uploads/2013/12/vaccine-paper-figure-2b.jpgvaccine paper Figure 2B2013-12-20T18:13:14+00:00monthlyhttps://kyleserikawa.com/2013/12/13/genetic-counseling-at-illumina/2013-12-13T18:02:19+00:00monthlyhttps://kyleserikawa.com/2013/11/25/some-collected-thoughts-on-the-challenges-of-priciple-investigators-as-managers/2022-06-19T00:16:50+00:00monthlyhttps://kyleserikawa.com/2013/11/14/when-business-takes-a-stand/2013-11-14T18:00:42+00:00monthlyhttps://kyleserikawa.com/2013/11/11/the-short-sword-doesnt-fall-far-from-the-weapons-rack/2013-11-11T18:08:16+00:00monthlyhttps://kyleserikawa.com/2013/11/04/what-do-labrador-retrievers-and-nfl-wide-receivers-have-in-common/https://kyleserikawa.com/wp-content/uploads/2013/11/dog-accelerometer.gifdog accelerometer2013-11-04T19:16:36+00:00monthlyhttps://kyleserikawa.com/2013/10/31/mobile-tech-and-the-challenge-and-opportunity-for-design/2013-10-31T21:35:57+00:00monthlyhttps://kyleserikawa.com/2013/10/28/tall-poppies-tall-corn-and-creating-the-right-environment/2013-10-28T15:15:14+00:00monthlyhttps://kyleserikawa.com/2013/10/04/one-small-wistful-story-about-the-shutdown/https://kyleserikawa.com/wp-content/uploads/2013/10/salmon-waves.jpgSalmon Waves2013-10-13T19:24:15+00:00monthlyhttps://kyleserikawa.com/2013/09/30/biopharma-should-choose-targets-using-a-baseball-style-draft/2013-10-02T07:00:06+00:00monthlyhttps://kyleserikawa.com/2013/09/23/premature-testification-is-not-a-laughing-matter/2013-09-23T16:03:29+00:00monthlyhttps://kyleserikawa.com/2013/09/20/transparency-and-the-invisible-hand-in-hospital-and-healthcare-costs/https://kyleserikawa.com/wp-content/uploads/2013/09/1375_figure2.jpg1375_Figure22013-09-20T18:56:46+00:00monthlyhttps://kyleserikawa.com/2013/09/18/fear-versus-fear-understanding-vaccination-rates/2013-09-18T20:44:09+00:00monthlyhttps://kyleserikawa.com/2013/09/16/priming-the-pump-biopharma-contributions-and-prescribing-patterns/https://kyleserikawa.com/wp-content/uploads/2013/09/figure-a1.pngFigure Ahttps://kyleserikawa.com/wp-content/uploads/2013/09/figure-a.pngFigure A2013-09-16T17:44:08+00:00monthlyhttps://kyleserikawa.com/2013/09/13/acid-burn-how-ocean-acidity-might-make-climate-change-worse/2013-09-13T16:22:43+00:00monthlyhttps://kyleserikawa.com/2013/09/11/mulally-and-microsoft/2013-09-11T17:22:28+00:00monthlyhttps://kyleserikawa.com/2013/09/09/jeff-bezos-is-the-anti-unbundler-or-can-the-founder-of-amazon-make-us-eat-our-greens/2013-09-09T16:03:14+00:00monthlyhttps://kyleserikawa.com/2013/09/06/what-would-you-want-to-do-with-genome-sequence-data/2013-09-06T17:03:36+00:00monthlyhttps://kyleserikawa.com/2013/09/05/hanging-with-the-herd-for-the-immunity-of-it-all/2013-09-05T15:47:11+00:00monthlyhttps://kyleserikawa.com/2013/09/04/the-good-the-difficult-and-the-reality-patients-in-the-digital-age/2013-09-04T19:12:44+00:00monthlyhttps://kyleserikawa.com/2013/08/30/what-85-million-could-get-the-nfl-thinking-about-the-nfl-concussion-settlement/2013-08-31T06:22:39+00:00monthlyhttps://kyleserikawa.com/2013/08/28/gaming-to-help-beat-cancer/2013-08-28T16:42:17+00:00monthlyhttps://kyleserikawa.com/2013/07/08/3d-printers-diy-bio-french-bistros-and-one-possible-future-path-for-drug-development/2013-08-27T23:55:48+00:00monthlyhttps://kyleserikawa.com/2013/07/10/getting-patients-back-to-normal/2013-08-27T23:55:03+00:00monthlyhttps://kyleserikawa.com/2013/07/15/undervalued-assets-in-biopharma-hiring-adaptability/2013-08-27T23:54:32+00:00monthlyhttps://kyleserikawa.com/2013/08/26/internet-access-is-a-public-and-private-health-issue/2013-08-27T21:05:39+00:00monthlyhttps://kyleserikawa.com/2013/08/24/batman-blockbusters-and-biopharma/2013-08-24T20:32:26+00:00monthlyhttps://kyleserikawa.com/2013/08/23/enter-citizen-science/2013-08-23T16:13:11+00:00monthlyhttps://kyleserikawa.com/2013/08/22/maternal-versus-paternal-effects-on-autism/2013-08-22T16:09:54+00:00monthlyhttps://kyleserikawa.com/2013/08/21/do-biopharma-workers-hate-their-jobs-answer-i-dont-think-so-but/2013-08-21T16:34:41+00:00monthlyhttps://kyleserikawa.com/2013/08/01/when-a-grand-old-scientist-talks-you-listen-maynard-olson-and-genomic-medicine/2013-08-21T06:49:43+00:00monthlyhttps://kyleserikawa.com/2013/08/02/pink-mustaches-or-disruptive-technologies-meet-the-freeways-of-la/2013-08-21T06:49:12+00:00monthlyhttps://kyleserikawa.com/2013/08/07/major-league-baseball-should-be-all-over-the-quantified-self-movement/https://kyleserikawa.com/wp-content/uploads/2013/08/graph3.pnggraph3https://kyleserikawa.com/wp-content/uploads/2013/08/graph2.pnggraph2https://kyleserikawa.com/wp-content/uploads/2013/08/graph1.pnggraph12013-08-21T06:48:31+00:00monthlyhttps://kyleserikawa.com/2013/08/09/more-developments-in-autism-prediction/2013-08-21T06:47:40+00:00monthlyhttps://kyleserikawa.com/2013/08/20/lack-of-replication-no-surprise-when-were-studying-really-complex-problems/2013-08-23T01:36:28+00:00monthlyhttps://kyleserikawa.com/2013/08/19/are-market-cap-and-present-cash-flows-the-best-way-to-measure-innovation/2013-08-19T17:33:24+00:00monthlyhttps://kyleserikawa.com/2013/08/16/what-does-the-hela-genome-agreement-imply-for-consent-and-genome-data-usage/2013-08-17T23:01:29+00:00monthlyhttps://kyleserikawa.com/2013/08/14/how-do-you-take-a-cheetahs-temperature/2013-08-14T16:09:18+00:00monthlyhttps://kyleserikawa.com/2013/08/13/finding-an-alka-seltzer-for-the-oceans/2013-08-13T16:33:29+00:00monthlyhttps://kyleserikawa.com/2013/08/12/are-biopharma-reagent-companies-sitting-on-a-pile-of-gold-or-at-least-poptarts/2013-08-12T16:22:46+00:00monthlyhttps://kyleserikawa.com/2013/08/05/why-everyone-should-worry-more-about-the-bees/2013-08-05T16:02:19+00:00monthlyhttps://kyleserikawa.com/2013/07/31/nothing-but-nets-applying-network-theory-to-the-workplace/https://kyleserikawa.com/wp-content/uploads/2013/06/network2.pngnetwork2https://kyleserikawa.com/wp-content/uploads/2013/06/network1.pngnetwork1https://kyleserikawa.com/wp-content/uploads/2013/06/venn-scientists-2.pngVenn Scientists (2)2013-08-01T07:09:07+00:00monthlyhttps://kyleserikawa.com/2013/07/19/maternal-immune-systems-autism-and-the-value-of-prediction/2013-07-19T21:23:31+00:00monthlyhttps://kyleserikawa.com/2013/07/18/internal-and-external-motivation-and-the-gsk-big-bonuses-for-a-successful-drug-initiative/2013-07-19T00:09:38+00:00monthlyhttps://kyleserikawa.com/2013/07/17/girls-g-a-m-e-s-stem-and-fun/2013-07-17T16:58:33+00:00monthlyhttps://kyleserikawa.com/2013/07/16/trying-to-keep-my-feet-on-the-ground-and-not-in-my-mouth/2013-07-16T16:11:57+00:00monthlyhttps://kyleserikawa.com/2013/07/12/dealing-with-disruption-publishing-houses-and-drug-development/2013-07-12T19:19:17+00:00monthlyhttps://kyleserikawa.com/2013/07/03/fielding-percentage-for-uk-surgeons/2013-07-09T20:05:26+00:00monthlyhttps://kyleserikawa.com/2013/07/02/cheetahs-hunting-a-coda-on-sensors/2013-07-02T17:09:46+00:00monthlyhttps://kyleserikawa.com/2013/07/01/cheetahs-hunting-redux-the-next-step-in-measuring-baseball-defense/2013-07-01T21:35:54+00:00monthlyhttps://kyleserikawa.com/2013/06/28/cheetahs-hunting-and-the-quantized-self/2013-07-01T16:58:29+00:00monthlyhttps://kyleserikawa.com/about/2013-07-01T00:57:55+00:00weekly0.6https://kyleserikawa.com/2013/06/24/gastric-bypass-surgery-and-the-ever-expanding-world-of-gxe-interactions/2013-06-28T05:45:05+00:00monthlyhttps://kyleserikawa.com/2013/06/26/why-derek-jeter-being-a-lousy-defensive-shortstop-gives-me-hope-for-innovation-in-industry/2013-06-26T18:10:02+00:00monthlyhttps://kyleserikawa.com/2013/06/21/metrics-and-the-heisenberg-quality-of-gathering-data-about-behavior/2013-06-22T00:16:29+00:00monthlyhttps://kyleserikawa.com/2013/06/20/a-genomics-researchers-take-on-the-global-health-metrics-conference-2013/2013-06-20T16:57:36+00:00monthlyhttps://kyleserikawa.com/2013/06/18/to-ted-or-not-to-ted-that-is-the-question-for-researchers/2013-06-19T06:52:26+00:00monthlyhttps://kyleserikawa.com/2013/06/16/not-losing-versus-playing-to-win-in-baseball-and-drug-development/2013-06-17T05:39:55+00:00monthlyhttps://kyleserikawa.com/2013/06/12/reigning-in-the-hyperbole-about-the-role-of-drug-development/2013-06-13T05:41:15+00:00monthlyhttps://kyleserikawa.com/2013/06/10/the-global-alliance-for-responsible-sharing-of-genomic-and-clinical-data-an-asilomar-conference-for-today/2013-06-11T06:20:30+00:00monthlyhttps://kyleserikawa.com/2013/06/03/85/2013-06-03T07:13:22+00:00monthlyhttps://kyleserikawa.com/2013/05/31/sea-turtles-natures-smartphone/2021-10-16T04:55:41+00:00monthlyhttps://kyleserikawa.com/2013/05/31/1-5-as-a-metaphor-for-targets-in-drug-development/2013-05-31T05:08:04+00:00monthlyhttps://kyleserikawa.com/2013/05/28/greenhouse-gas-is-changing-ocean-ecosystems/2013-05-28T04:19:19+00:00monthlyhttps://kyleserikawa.com/2013/05/16/some-thoughts-in-response-to-a-article-on-why-drug-development-is-so-hard/2013-05-17T05:48:45+00:00monthlyhttps://kyleserikawa.com/2013/05/13/sequencing-seattle-an-idea-for-the-future-of-the-northwest/2013-05-13T02:59:49+00:00monthlyhttps://kyleserikawa.com/2013/05/12/drug-development-lets-play/2013-05-12T19:22:32+00:00monthlyhttps://kyleserikawa.com/2013/05/12/finding-parallels-between-baseball-and-drug-development/2013-05-12T19:15:04+00:00monthlyhttps://kyleserikawa.com/2013/05/12/what-is-this-blog-about/2024-02-21T22:34:55+00:00monthlyhttps://kyleserikawa.comdaily1.02024-02-21T22:34:55+00:00